

PATENT Attorney Docket No. 7372/72249

# THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ASAKO et al.

Application No. 10/004,115

Filed: December 6, 2002

For: PROCESS FOR PRODUCING OPTICALLY ACTIVE 4-HALO-3-

HYDROXYBUTANOATE

October 17, 2002

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

In re Appln. of ASAKO et al. Application No. 10/004,115

The Information Disclosure Statement is being filed:

- (X) within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits: or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- () **after** (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:
  - () the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).

() the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).

- () **after** the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
- after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).

NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.

### **Copies of the References**

OF

- (X) Copies of the references listed on the enclosed Form 1449 are enclosed herewith.
- (X) A copy of the European Search Report is enclosed herewith.

In re Appln. of ASAKO et al. Application No. 10/004,115

() The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLI	Status (check one)			
U.S. APPLICATIONS U.S. FILING DATE		PATENTED	PENDING	ABANDONED
1				
2.				
3.				

#### Statement under 37 CFR 1.97(e)

- () The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- () The **undersigned** hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

#### Statement under 37 CFR 1.704(d)

() The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

In re Appln. of ASAKO et al. Application No. 10/004,115

#### Fees

- (X) **No fee** is owed by the applicant(s).
- () The **IDS Fee of \$180** under 37 CFR 1.17(p) is enclosed herewith.

#### **Method of Payment of Fees**

- () Attached is a check in the amount of \$180.00.
- () Charge Deposit Account No. 06-1135 in the amount of \$ . (A duplicate copy of this communication is enclosed for that purpose.)

### **Authorization to Charge Additional Fees**

(X) If any additional fees are owed in connection with this communication, please charge Deposit Account No. 06-1135. (A duplicate copy of this communication is enclosed for that purpose.)

### Instructions as to Overpayment

- (X) Credit Account No. 06-1135.
- () Refund

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Kendrew H. Colton

Registration No. 30,368

1801 K Street, N.W.

Suite 400L

Washington, D.C. 20006-1201

Telephone: (202) 419-7000

Facsimile: (202) 419-7007

\o,			ری د	8
TOO	1	7	2002	FFICE
0				2

12	
Application Number	10/004,115
Filing Date	December 6, 2001
First Named Inventor	ASAKO et al.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket	7372/72249
	Application Number  Filing Date  First Named Inventor  Art Unit  Examiner Name

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines		
Initials*	No.1	Number-Kind Code <sup>2</sup>	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear		
		US-					
		US-					
		US-					
		US-					
	ļ	US-					
		US-					
		US-					
		US-					
		US-		_			
	<u> </u>	US-					
		US-					
		US-					
		US-					
		US-					

		FOREIG	GN PATENT DO	CUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines	Γ
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup>	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Τe
	EP 0 967 271 A1		12/29/1999 Yasohara et al.			
		EP 1 013 758 A2	06/29/2000	Kimoto et al.		
		EP 0 606 899 A2	07/20/1994	Matsuyama et al.		
		WO 99/42590	08/26/1999	Petersen et al.		
		WO 93/18138	08/16/1993	Kula et al.		

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

					5
- /					8
- 1	በቦፐ	1	7	2002	

	OCT	1 7	200	2

PTO/SB/0				Application Number	10/004,115	THADEMARK
Substitute for Form PTO 1449				Filing Date	December 6, 2001	MADE
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				First Named Inventor	ASAKO et al.	
				Art Unit	Not Yet Assigned	
				Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket	7372/72249	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T/
		Kataoka et al., "Stereoselective Reduction of Ethyl 4-Chloro-3-Oxobutanoate by <i>Escherichia Coli</i> Transformant Cells Coexpressing the Aldehyde Reductase and Glucose Dehydrogenase Genes," Appl. Microbiol Biotechnol, 51: pp. 486-490 (199)	
		Database EMBL Online - 12 October 1998 - Kımura, M., "Ciibberelia Zeae Gene For Reductase," Retrieved from EBI - Database Accession No. AC014493; 074646 - XP 002209648	
		Database WPI, Week 198546, 1985, Derwent Publications Ltd., London, GB; AN 1985-287883 - XP-002209642	
		Database CA Online - Chemical Abstracts Service, Columbus, Ohio, US; Takahashi et al., "Microbial Production of Dalphaamino Acids," Retrieved from STN, Database Accession No. 107;76090 - XP-002209641	
Examine Signature		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.